Literature DB >> 239221

Effect of thioridazine, clozapine and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turnover rate of dopamine in striatum and nucleus accumbens.

B Zivkovic, A Guidotti, A Revuelta, E Costa.   

Abstract

In rats, a single injection of antipsychotic drugs produced a transitory change in the kinetic state of tyrosine hydroxylase (TH) in striatum and nucleus accumbens. The affinity of TH for 2-amino-4-hydoxy-6,7-dimethyl-5,6,7,8-tetrahydropterine (DMPH4) and the Vmax with respect ot tyrosine were increased. The relative potencies of anti-psychotics to change the kinetics of TH in striatum and nucleus accumbens when injected into rats were measured in the presence of 0.4 mM DMPH4. The doses of methiothepin, pimozide and halopridol which increased the affinity for DMPH4 of striatal TH were lower than those required to produce a similar change in nucleus accumbens. In contrast, thioridazine and clozapine were more effective in nucleus accumbens than in striatum. Chlorpromazine was equally active in these two tissues. Haloperidol increased the turnover rate of dopamine in striatum with doses that are relatively smaller than those required in the nucleus accumbens. Clozapine was more active in increasing turnover rate of dopamine in nucleus accumbens; the activity of chlorpromazine in these two tissues was equal. These results suggest that antipsychotics with high incidence of extrapyramidal side effects affect the nigrostriatal dopaminergic pathway selectively.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 239221

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  The regulation of striatal tyrosine hydroxylase. Effects of gamma hydroxybutric acid and healperidol.

Authors:  B Zivkovic; A Guidotti; E Costa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

Review 3.  Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.

Authors:  K Gale; M Casu
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

Review 4.  Antidepressant and antipsychotic agents.

Authors:  R A Lahti
Journal:  Naturwissenschaften       Date:  1979-08

5.  Modification of the tyrosine hydroxylase assay. Increased enzyme activity in the presence of ascorbic acid.

Authors:  P Lerner; P Nosé; M M Ames; W Lovenberg
Journal:  Neurochem Res       Date:  1978-10       Impact factor: 3.996

6.  Clozapine-induced dopamine release in the medial prefrontal cortex is augmented by a moderate concentration of locally administered tyrosine but attenuated by high tyrosine concentrations or by tyrosine depletion.

Authors:  George E Jaskiw; Bobbi Kirkbride; Erica Newbould; Damon Young; Valerie Durkalski; Rodolfo Bongiovanni
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

7.  Differential effects of haloperidol and clozapine on attention.

Authors:  M Cheal
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 8.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 9.  Tyrosine hydroxylase regulation in the central nervous system.

Authors:  J M Masserano; N Weiner
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

10.  No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia.

Authors:  Heon-Jeong Lee; Seung-Gul Kang; Jung-Eun Choi; Young-Min Park; Se-Won Lim; Min Kyu Rhee; Seung-Hyun Kim; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.